-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NSEBXZx7NtbuL/dkzif4jeUKYF3cBktsZ9EMd2dmRHkvnKWuhhWa3mBXdXbDvYwp FTszt1LbmXWyG4jRu+/8VA== 0000950109-96-006849.txt : 19961023 0000950109-96-006849.hdr.sgml : 19961023 ACCESSION NUMBER: 0000950109-96-006849 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19961015 ITEM INFORMATION: Other events ITEM INFORMATION: Change in fiscal year FILED AS OF DATE: 19961022 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON LIFE SCIENCES INC /DE CENTRAL INDEX KEY: 0000094784 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870277826 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-06533 FILM NUMBER: 96646370 BUSINESS ADDRESS: STREET 1: 1601 TRAPELO RD STREET 2: RESERVOIR PL CITY: WALTHAM STATE: MA ZIP: 02154 BUSINESS PHONE: 6178908263 MAIL ADDRESS: STREET 2: 1601 TRAPELO RD CITY: WALTHAN STATE: MA ZIP: 02154 FORMER COMPANY: FORMER CONFORMED NAME: GREENWICH PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: STRATEGIC MEDICAL RESEARCH CORP /DE DATE OF NAME CHANGE: 19790521 8-K 1 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) October 15, 1996 ---------------- BOSTON LIFE SCIENCES, INC. --------------------------------------------------------- (Exact name of registrant as specified in its charter) Delaware 0-6533 87-0277826 - --------------------- ------ -------------------- (State or other jurisdiction (Commission File No.) (I.R.S. Employer of incorporation or Identification No.) organization) 33 Newbury Street, Suite 300 Boston, Massachusetts 02116 - ---------------------------------------- ---------- (Address of principal executive offices) Zip Code Registrant's telephone number, including area code (617) 425-0200 --------------- Item 5. Other Events. ------------- On October 15, 1996, Boston Life Sciences, Inc., a company engaged in the research and development of novel treatments for cancer, autoimmune diseases, and central nervous system disorders, announced that the Company had received notices of allowance for two patent applications licensed from Children's Hospital and Harvard University. The notice of allowances pertain to patent applications covering the Company's Central Nervous System growth factor, Axogenesis Factor 1 (AF1), and the use of transcription factors to control the expression of MHC Class II molecules for the potential treatment of autoimmune diseases. These notices of allowances strengthen the company's position in these two important areas. The allowed patent on transcriptional control of MHC Class II molecules, together with the recent licensing of patent applications covering C-maf and NIP-45, positions the Company as a potential leader in the field of immune system regulation. The Company is hopeful that its licenses to and development of these important discoveries will eventually yield novel products for the treatment of autoimmune diseases and allergies. The Company believes that AF1 is a potential treatment for stroke and spinal cord injuries. The Company continues to make substantial preclinical development progress with AF1 and hopes to be able to begin to bring it into human clinical testing in 1998. Item 8 Exhibits. -------- The following Exhibits are filed as part of this report on Form 8-K 99.1 Press Release, dated October 15, 1996. SIGNATURES ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto authorized. BOSTON LIFE SCIENCES, INC. Dated: October 22, 1996 By: /s/ Joseph Hernon ------------------ Joseph Hernon Chief Financial Officer BOSTON LIFE SCIENCES, INC. CURRENT REPORT ON FORM 8-K EXHIBIT INDEX
Exhibit No. Page - ----------- ---- 99.1 Press Release, dated October 15, 1996 5
EX-99.1 2 NEWS RELEASE Exhibit 99.1 ***FOR IMMEDIATE RELEASE*** BOSTON LIFE SCIENCES RECEIVES NOTICE OF TWO PATENTS COVERING AXOGENESIS FACTOR 1 (AF1) AND AUTOIMMUNE PROGRAM Boston, Mass - October 15, 1996-- Boston Life Sciences, Inc. (NASDAQ: BLSI) announced that the Company had received notices of allowance for two patent applications licensed from Children's Hospital and Harvard University. The notice of allowances pertain to patent applications covering the company's Central Nervous System growth factor, Axogenesis Factor 1 (AF1), and the use of transcription factors to control the expression of MHC Class II molecules for the potential treatment of autoimmune diseases. "These notices of allowances strengthen our position in these two important areas. We believe that the allowed patent on transcriptional control of MHC Class II molecules, together with the recent licensing of patent applications covering C-maf and NIP-45, positions the Company as a potential leader in the field of immune system regulation. We are hopeful that its licenses to and development of these important discoveries will eventually yield novel products for the treatment of autoimmune diseases and allergies," stated Dr. Marc Lanser, Chief Scientific Officer of BLSI. "We continue to be very excited about AF1 as a potential treatment for stroke and spinal cord injuries, so we are obviously gratified to have received a patent allowance on this important molecule. We continue to make substantial preclinical development progress with AF1 and hope to be able to begin to bring it into human clinical testing in 1998," added Dr. Lanser. BLSI is engaged in the research and development of novel treatments for cancer, autoimmune diseases, and central nervous system disorders. BLSI's products in clinical trials or in pre-clinical development include the above-mentioned anti-angiogenesis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; THERAFECTIN(R) for the treatment of Rheumatoid Arthritis; and transcription factors to control the expression of molecules associated with autoimmune disease and allergies. For additional information contact: Marc E. Lanser, M.D. Chief Scientific Officer 617-425-0200 -----END PRIVACY-ENHANCED MESSAGE-----